Abstract 1202 Figure 1 LS Mean eGFR over Time. Analysis of AURORA 2 patients includes data from pre-treatment baseline of AURORA 1, 12 months in AURORA 1 and up to 25 months in AURORA 2 (including 4- week post-treatment visit). Renal function assessed with corrected eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) using a prespecified ceiling of 90 mL/min/1.73 m2. CI, confidence interval; eGFR, estimated glomerular filtration rate; FUP, follow-up visit (4-week post-treatment visit); LS Mean, least squares mean.

Abstract 1202 Table 1 Overall Summary of Adverse Events

	Control (n=100)	Voclosporin (n=116)
	n (%)	n (%)
Any AE	80 (80.0)	100 (86.2)
Treatment-related AE	21 (21.0)	28 (24.1)
Serious AE	23 (23.0)	21 (18.1)
Serious Treatment-related AE	2 (2.0)	1 (0.9)
AE Leading to Study Drug Discontinuation	17 (17.0)	11 (9.5)
Death[*]	4 (4.0)	0
Treatment-related Death	0	0

[*]The four deaths in the control arm were due to pulmonary embolism (n=1) and coronavirus infection (n=3). Includes adverse events starting on or after the first dose of study drug in AURORA 2 up to 30 days after the last dose and all events of death reported during study follow-up. Adverse events were aggregated by System Organ Class and Preferred Term and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0. AE, adverse event.

eGFR remained stable throughout the study period and the significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. These data provide evidence of a long-term treatment benefit of VCS in patients with LN.

Disclosures AS reports payments for Aurinia Pharmaceuticals Inc. speaker bureaus; primary investigator for Aurinia Pharmaceuticals Inc. clinical trials; advisory fees from Eli Lilly, AstraZeneca, GlaxoSmithKline and Kezar Life Sciences. YKOT reports research grants from commercial organizations including an unrestricted research grant from GlaxoSmithKline and Aurinia Pharmaceuticals Inc.; primary investigator for Aurinia Pharmaceuticals Inc. clinical trials; consultancy fees paid to institution from Aurinia Pharmaceuticals Inc., Novartis, GlaxoSmithKline, KezarBio, Vifor Pharma and Otsuka Pharmaceuticals. CC, NE, and HL are employees and shareholders of Aurinia Pharmaceuticals, Inc. HL is an employee and shareholder of Aurinia Pharmaceuticals, Inc. Data first presented by Saxena A et al. at the EULAR Congress June 1-4, 2022. Editorial support provided by MediComm Partners Ltd. Aurinia Pharmaceuticals Inc. provided funding for the study and presentation.


BLOCKADE OF THE MECHANISTIC TARGET OF RAPAMYCIN ELICITS RAPID AND LASTING IMPROVEMENT OF DISEASE ACTIVITY THROUGH RESTRAINING PRO-INFLAMMATORY T CELL LINEAGE SPECIFICATION IN PATIENTS WITH ACTIVE SLE

Zhi-Wei Lai, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Julie Yu, Maha Dawood, Ricardo Garcia, Hajra Tily, Lisa Francis, Stephen V Faraone, Paul E Phillips, Andras Perl. *Division of Rheumatology, Departments of Medicine, Microbiology and Immunology, and Biochemistry and Molecular Biology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York 13210*

Background Systemic lupus erythematosus (SLE) patients exhibit proinflammatory lineage development in the immune system that has been attributed to mechanistic target of rapamycin (mTOR) activation. Moreover, mTOR activation has also been shown in resident cells of tissues affected by end-organ damage. Therefore, safety, tolerance, and efficacy of rapamycin were examined in prospective [1] and retrospective biomarker-driven clinical trials [2,3].

Methods 40 patients having active disease and unresponsive or intolerant to conventional medications were enrolled in a prospective study [1]. Sirolimus was started at 2 mg/day with dosage adjusted to tolerance and 6-15 ng/ml trough levels. Disease activity was evaluated by BILAG, SLEDAI, and prednisone use over 12 months. Blood samples of 56 matched healthy subjects were obtained as controls for

Abstract 1203 Figure 1   Metabolic control of pro-inflammatory T-cell lineage specification in SLE. Schematic molecular order of pathways upstream and downstream of activation of the mechanistic target of rapamycin (mTOR) in SLE. mTOR is activated on the surface of lysosomes in a state of amino acid sufficiency (V/L/I/Q/Kyn)[4]. Oxidative stress, in particular cysteine oxidation, also activates mTORC1 through association with Rheb[5]. Given the results of our randomized double-blind placebo-controlled clinical trial showing that therapeutically effective reversal of GSH depletion by NAC blocks mTORC1 *in vivo*[6], GSH depletion will be considered the primary metabolic checkpoint of pro-inflammatory T-cell lineage specification in SLE. The depletion of GSH will be mechanistically connected to the depletion of cysteine (Cys) and NADPH and to the accumulation of kynurenine (Kyn) which have been uncovered by comprehensive metabolome studies of PBL from SLE and healthy subjects matched for age, gender, and ethnicity and processed in parallel [7]. Blockade of mTOR with rapamycin reverses the depletion of effector-memory CD8 T cells and Tregs and the expansion of pro- inflammatory CD4-CD8- double-negative T cells in patients with active SLE in vivo [1]. Red and blue arrows reflect direction of changes in SLE.

immunometabolic outcomes monitored at each visit. The effects of sirolimus was also investigated retrospectively in 73 patients with or without nephritis [2] and 187 patients with lupus nephritis [3].

Results As primary clinical efficacy endpoint, SLEDAI disease activity scores were reduced over 12 months in 16/29 patients (55%). 19/29 patients (65.5%) met criteria for SLE Responder Index (SRI). Arthritis, rash, pyuria, and hypocomplementemia improved among SLEDAI components, while cardiopulmonary, musculoskeletal, mucocutaneous, and vasculitis BILAG organ-domain scores also declined. Prednisone use diminished from 24.3 ± 4.7 mg/day to 7.2 ± 2.3 mg/day ($p<0.0009$). Sirolimus expanded $CD4^+CD25^+FoxP3^+$ Tregs and $CD8^+$ memory T cells and inhibited IL-4 and IL-17 production by $CD4^+$ and $CD4^-CD8^-$ double-negative T cells after 12 months. $CD8^+$ memory T cells were selectively expanded in SRI- responders [1].

In 12 patients of 73 patients who had lupus nephritis, proteinuria ($p=0.0287$), hematuria ($p=0.0232$), anti- DNA antibody levels ($p=0.0028$) and steroid use were reduced ($p=0.0200$). In the non-renal cohort of 61 patients, anti-DNA antibody levels ($p=0.0332$) and steroid use were reduced ($p=0.0163$). Both in the renal and non-renal cohorts, C3 (renal $p=0.0070$; non-renal $p=0.0021$) and C4 complement levels were increased (renal $p=0.0063$; non-renal $p=0.0042$)

Adverse effects of mouth sores (2/73), headaches (1/73), and gastrointestinal discomfort were noted in a minority of patients (6/73). Sirolimus was only discontinued in two of 73 patients due to headache and recurrent infections, respectively [2].

The retrospective study of 187 LN patients evaluated mTOR activation in renal tissue of 187 LN patients in comparison to 20 diabetic nephropathy (DN) patients, 10 minimal change disease (MCD) patients, and 10 normal controls (NCs) [3]. mTOR complexes 1 and 2 (mTORC1/2) were activated in podocytes, mesangial cells, endothelial cells and tubular epithelial cells of LN patients as compared with those with MCD or NC. The glomerular mTORC1 activation was higher in LN patients compared with DN patients. mTORC1, but not mTORC2, activation strongly correlated with crescent formation, interstitial inflammation and fibrosis and serum albumin, complement C3, and proteinuria. mTORC1 activation was identified as a prognostic marker in LN patients.

Conclusions These studies suggests that sirolimus is well tolerated and exerts long-term therapeutic efficacy in controlling renal and non-renal manifestations of SLE. Renal mTORC1 activation may predict clinical prognosis and therapeutic response to sirolimus in patients with LN.

Lay summary Rapamycin, also called as sirolimus, has been newly identified as a new treatment with promising clinical effectiveness and well-defined mechanism of active in patients with moderate to severe SLE.

REFERENCES

1. Lai, Z. et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet 2018;**391**: 1186- 1196
2. Piranavan, P., and Perl, A. Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - A 21-year follow-up study of 73 patients. Clin. Immunol. 2021;**229**: 108781
3. Mao, Z. et al. Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. Rheumatology, 2022; keac037
4. Perl, A. Mechanistic Target of Rapamycin Pathway Activation in Rheumatic Diseases. Nat. Rev. Rheumatol. 2016; **12**, 169–182
5. Yoshida, S. et al. Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway. J. Biol. Chem. 2011;**286**, 32651–32660
6. Lai, Z.-W. et al. N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 2012;**64**, 2937–2946
7. Perl, A. et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 2015;**11**, 1157–1174

Lupus-Targeted Therapeutics

1204   IMPROVING LYMPHATIC FUNCTION TO REDUCE B CELL RESPONSES IN LUPUS

[1,2†††]William G Ambler*, [1,3]Mir Howlader, [1,4,†]Madhavi Latha S Chalasani, [1]Ethan S Seltzer, [1,4]JiHyun Sim, [4]Jinyeon Shin, [1,6,‡]Noa Schwartz, [1,7,¶]Dragos Dasoveanu, [8]Camila B Carballo, [5,§]Ecem Sevim, [2,6]Salma Siddique, [††], [8,9]Scott Rodeo, [6]Doruk Erkan, [5]Raghu P Kataru, [5]Babak Mehrara, [1,2,4,6,10]Theresa T Lu*. [1]Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute; New York, NY, USA; [2]Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery; New York, NY, USA; [3]Biochemistry, Structural Biology, Cell Biology, Developmental Biology and Molecular Biology Graduate Program, Weill Cornell Medicine; New York, NY, USA; [4]Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA; [5]Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center; New York, NY, USA; [6]Rheumatology, Department of Medicine, Hospital for Special Surgery; New York, USA; [7]Physiology, Biophysics, and Systems Biology Graduate Program, Weill Cornell Medicine, New York, NY USA; [8]Orthopedic Soft Tissue Research Program, Hospital for Special Surgery Research Institute; New York, NY, USA; [9]Department of Orthopedics, Hospital for Special Surgery; New York, NY, USA; [10]Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA; †††Current address: NIAMS, Bethesda, MD, USA; †Current address: Mnemo Therapeutics; Princeton, NJ, USA; ‡Current address Department of Medicine (Rheumatology), Albert Einstein College of Medicine/Montefiore Medical Center; Bronx, NY, USA6; §Current address Department of Medicine, Montefiore Medical Center; Bronx, NY, USA; ¶Current address Department of Cancer Immunology, Genentech; South San Francisco, CA, USA; ††Current address Nemours Hospital for Children, Wilmington, DE, USA

Background In SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.

Methods We examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody + non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTEN$^{f/f}$ Flt4-Cre^{ER} model with increased lymphatic numbers and function.

Results SLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTEN$^{f/f}$ Flt4-Cre^{ER} mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.

Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.

Conclusions Our results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in SLE.

Lupus 21st Century 2022 Abstract

1205   TREATMENT OF LUPUS-PRONE BXSB MICE WITH A MODULATABLE CAR T CELL SYSTEM TARGETING CD19

[1]Ivo Rimann, [1]Hua Huang, [1]Parker Mace, [1]Rosana Gonzalez-Quintial, [1]Eduardo Laborda, [2]Sophie Viaud, [1]Hannah Mora, [1]Argyrios N Theofilopoulos, [2]Travis S Young, [1]Dwight H Kono. [1]The Scripps Research Institute; [2]Calibr at Scripps Research

Chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated efficacy in treating active lupus in both human and mouse lupus. However, a significant limitation of this approach is immunodeficiency due to the long-term depletion of B cells. To address this issue, we studied the potential of a switchable CAR (sCAR) T cell system targeting CD19 to transiently eliminate B cells and provide therapeutic benefit with less immunosuppression. This approach consists of a CAR that, instead of targeting CD19 directly, binds to a soluble antiCD19 Fab switch with a short